Advanced Bladder Cancer VL

EV-201 Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma Journal Club – Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the EV-201 study. EV-201 is a multicentre, single-arm, phase 2 study of enfortumab vedotin in patients with locally advanced or metastatic urothelial carcinoma previously treated with PD-1 or PD-L1 inhibitors. Dr. Wallis and Dr. Klaassen review Cohort 2 which included adults with an Eastern Cooperative Oncology Group performance status score of 2 or...

EV-103 Cohort K, Enfortumab Vedotin Monotherapy or in Combination With Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer – Jonat...

Details
Jonathan Rosenberg joins Alicia Morgans to discuss Cohort K of the EV-103 trial assessing the efficacy of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. Cohort K is one of several cohorts in a multi-cohort phase 1B2 study of enfortumab combined with multiple differ...

Molecular Subtyping and Neoadjuvant Chemotherapy in Bladder Cancer - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss a publication entitled, “Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.” This study is investigating how molecular subtypes impact pathological response and survival in patients receiving preoperative cisplatin-based chemotherapy. This study shows that tumor classification by gene expression profiling and...

Pembrolizumab Alone or Combined With Chemotherapy vs Chemotherapy As First-Line Therapy for Advanced Urothelial Carcinoma in the KEYNOTE-361 Trial Journal Club – Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss a Lancet Oncology publication on the KEYNOTE-361 trial, pembrolizumab alone, or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma: A randomized open-label phase three trial. The authors of this trial assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemothe...

CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the CheckMate 274 publication, “Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.” The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. The authors of this publication assigned patients with muscle-invasive urothelial carcinoma who had undergone radical surgery t...

The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta

Details
In this conversation, Arlene Siefker-Radtke and Shilpa Gupta join Patrick Hensley to discuss the role of risk-stratified neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer who are undergoing radical cystectomy. Drs. Siefker-Radtke and Gupta explain how systemic chemotherapy can be very challenging for bladder cancer patients due to the long-term side effects it can cause, alo...

Overall Response Rate After Immune-Checkpoint Inhibitor Initiation and Post-ICI PFS in Patients With Advanced Urothelial Carcinoma - Dimitrios Makrakis

Details
Petros Grivas is joined by Dimitrios Makrakis to discuss his multi-institutional retrospective cohort study of patients with advanced urothelial carcinoma (UC) who received platinum-based chemotherapy in the first line, followed by second-line immune checkpoint inhibitor (ICI). In this study, the timely question of how the duration of response to immune checkpoint inhibitor may be interpreted as p...

Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas

Details
In this conversation with Alicia Morgans, Rafee Talukder and Petros Grivas share data that investigates comparing the outcomes in patients who received prior intravesical BCG, and those patients who progressed and then required immune checkpoint inhibitors, to see if prior BCG therapy had an effect on the response on immune checkpoint inhibitors. Their hypothesis was, that patients who received BC...

Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective - Scott Tagawa

Details
Scott Tagawa joins Sam Chang to highlight the key topics of his discussion at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022. Dr. Tagawa provided a clinical perspective on antibody-drug conjugates in the treatment of urothelial carcinoma. Biographies: Scott T. Tagawa, MD, Associate Professor of Clinical Medicine, Clinical Urology, Medical Director, Genitourin...

Final Analysis of the ATLANTIS Rucaparib Arm - Simon Crabb

Details
Alicia Morgans is joined by Simon Crabb to discuss the analysis he presented at 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium regarding the rucaparib arm in the ATLANTIS trial among patients with metastatic urothelial carcinoma (mUC). ATLANTIS is a randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following c...
email news signup